Literature DB >> 23182728

Development of a brief self-report questionnaire for screening putative pre-psychotic states.

Chen-Chung Liu1, Yin-Jing Tien, Chun-Houh Chen, Yen-Nan Chiu, Yi-Ling Chien, Ming H Hsieh, Chih-Min Liu, Tzung-Jeng Hwang, Hai-Gwo Hwu.   

Abstract

BACKGROUND: Several self-report instruments were developed to capture psychotic prodrome, and were claimed to have good predictive validity. The feasibility of screening is questionable considering the heterogeneity of the targeted populations and the negative ramifications of false positive identification. This study developed a questionnaire using data covering a wide range of clinical characteristics.
METHODS: One hundred and eleven putative pre-psychotic participants, 129 normal comparison subjects, and 95 non-psychotic psychiatric outpatients completed a 231-item questionnaire comprising a 110-item Wisconsin psychotic prone scale, 74-item schizotypal personality questionnaire, 33-item basic symptoms, and 14-item cognitive symptoms. Items showing the best discriminating power, estimated using chi-square statistics with Bonferroni correction, were extracted to create a brief version. A two-stage cut-off approach emphasizing specific items was applied to maximize sensitivity and specificity. The concurrent validity of the proposed approach was estimated using a ten-fold cross-validation procedure.
RESULTS: A 15-item self-report questionnaire was developed. Respondents checking at least eight items, or those checking three to seven items including any of the three referring to feeling stress in crowds, aloofness, and perceptual disturbance, would be considered putatively pre-psychotic with the largest sensitivity+specificity (0.784+0.705=1.489). This cut-off selection was the best estimate by calculating 1000 permutations in the cross-validation procedure.
CONCLUSIONS: This investigation proposes a different orientation for applying questionnaires to screen putative pre-psychotic states, with less emphasis on attenuated psychotic symptoms and predictive values. Besides providing a handy tool for increasing awareness and referral, the instructions of such a screening questionnaire should be carefully worded.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23182728     DOI: 10.1016/j.schres.2012.10.042

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  The Reliability and Validity of Liu´s Self-Report Questionnaire for Screening Putative Pre-Psychotic States (BQSPS) in Adolescents.

Authors:  D Núñez; V B Arias; S Campos
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

2.  Screening nursing students to identify those at high risk of poor mental health: a cross-sectional survey.

Authors:  Der-Yun Hsiung; Ching-Lun Tsai; Ling-Chun Chiang; Wei-Fen Ma
Journal:  BMJ Open       Date:  2019-06-25       Impact factor: 2.692

3.  Evidence for Specific Associations Between Depressive Symptoms, Psychotic Experiences, and Suicidal Ideation in Chilean Adolescents From the General Population.

Authors:  Daniel Núñez; Pía Monjes; Susana Campos; Johanna T W Wigman
Journal:  Front Psychiatry       Date:  2021-01-28       Impact factor: 4.157

Review 4.  Psychotic-Like Experiences: A Challenge in Definition and Assessment.

Authors:  Barbara Hinterbuchinger; Nilufar Mossaheb
Journal:  Front Psychiatry       Date:  2021-03-29       Impact factor: 4.157

5.  Efficiency of an Online Health-Promotion Program in Individuals with At-Risk Mental State during the COVID-19 Pandemic.

Authors:  Ching-Lun Tsai; Cheng-Hao Tu; Jui-Cheng Chen; Hsien-Yuan Lane; Wei-Fen Ma
Journal:  Int J Environ Res Public Health       Date:  2021-11-12       Impact factor: 3.390

6.  Psychometric properties of the brief self-report questionnaire for screening putative pre-psychotic states and validation of clinical utility in young adult.

Authors:  Shih-Kuang Chiang; Pei-Ti Chen; Chen-Chung Liu
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.